Test Code 1DIS Human Leukocyte Antigens (HLA) A-B-C Disease Association Typing Low Resolution, Blood
Specimen Required
Container/Tube: Yellow top (ACD solution A or B)
Specimen Volume: 6 mL
Collection Instructions: Send whole blood in original tube. Do not aliquot.
Additional Information: Specimen acceptability is based on extracted DNA concentration and not sample age.
Forms
If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.
Secondary ID
609354Useful For
Determining class I human leukocyte antigens (HLA) on specimens for those patients who have become refractory to platelet transfusions and identify potential disease associations or markers for drug hypersensitivity
Method Name
Polymerase Chain Reaction (PCR)/Next-Generation Sequencing (NGS)
Reporting Name
HLA-A-B-C DisAssoc Typing LowRes,BSpecimen Type
Whole Blood ACDSpecimen Minimum Volume
3 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole Blood ACD | Ambient (preferred) | ||
Refrigerated |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Human leukocyte antigens (HLA) are regulators of the immune response. HLA class I typing is used to identify HLA-matched platelets for alloimmunized refractory patients and identify presence of HLA antigens associated with a number of diseases or as drug hypersensitivity markers Class I HLA antigens include A, B, and C loci. This assay is designed to provide low-to-medium resolution for HLA class I typing (A, B, C). Low-to-medium resolution defines the typing at the antigen level (first field). This contrasts with high-resolution typing, which defines typing at the allele (molecular) level (second field or higher).
Reference Values
Not applicable
Interpretation
Interpretation depends on the rationale for ordering the test.
Method Description
Next-generation sequencing is used to type for Class I alleles (A, B, and C) from genomic DNA. This method uses strictly controlled polymerase chain reaction (PCR) conditions for DNA amplification. The PCR amplicons are processed and sequenced via the Illumina MiSeq instrument. The output files are analyzed in provided software, which compares the data against the IMGT/HLA database to assign the molecular typing.(Package inserts: Holotype HLA Kit. Omixon; v3.0.1, 08/16/2019; NGSgo HLA Kit. GenDx; v2, 02/2021)
For resolution of an allelic ambiguity or in select cases, the following additional methodologies may be utilized:
-Sequence-based typing (SBT) by Sanger sequencing(Package insert: SeCore Sequencing and GSSP Kits. One Lambda, Inc; Rev 3, 02/06/2021)
-SBT by sequence-specific primers (SSP)(Package insert: Olerup SSP HLA typing kits including Taq Polymerase. CareDx; Rev 04, 12/2020)
-Reverse sequence-specific oligonucleotides (SSO)(Package insert: LABType SSO Typing Test. One Lambda, Inc.; Rev 04, 11/11/2019)
Day(s) Performed
Monday, Thursday
Performing Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81372
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
1DIS | HLA-A-B-C DisAssoc Typing LowRes,B | 96629-1 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
1DA02 | ABC DisAssoc Comment | 96625-9 |
1DA03 | A - 1 Equivalent | 13298-5 |
1DA04 | A - 2 Equivalent | 13298-5 |
1DA05 | A - 1 Molecular | 78014-8 |
1DA06 | A - 2 Molecular | 78014-8 |
1DA07 | B - 1 Equivalent | 13299-3 |
1DA08 | B - 2 Equivalent | 13299-3 |
1DA09 | B - 1 Molecular | 78015-5 |
1DA10 | B - 2 Molecular | 78015-5 |
1DA11 | Bw - 1 Equivalent | 96633-3 |
1DA12 | Bw - 2 Equivalent | 96633-3 |
1DA13 | C - 1 Equivalent | 13302-5 |
1DA14 | C - 2 Equivalent | 13302-5 |
1DA15 | C - 1 Molecular | 96636-6 |
1DA16 | C - 2 Molecular | 96636-6 |
LRTM1 | Test Method | 85069-3 |